Discover More About Us

Using high throughput methodologies, we identify the ideal reaction conditions for preparing the active pharmaceutical ingredients (API) to be efficiently manufactured in continuous flow. The result is a high yield of medical grade API with the least toxic waste and the best opportunity for production on scale. 

Continuity Pharma has been able to prove the effectiveness of this methodology for multiple APIs. We are identifying the best API targets based on data from the FDA, CDC, WHO, and HHS where they identify prescription drugs suffering from supply chain problems. Continuity Pharma has created an assessment tool to evaluate each drug on this “master list” to answer three key questions:

1. Is it truly an essential medicine?
2. What is the expectation for technical success in converting it to a portable modular continuous manufacturing system?
3. What is the market viability of such a system?

Continuity Pharma’s R & D efforts have two primary objectives. The first objective is to evolve our API production to incorporate continuous fill and finishing capabilities, creating an “end-to-end” continuous manufactured drug process that is fully portable and modular. 

The second R & D objective is to design and build the manufacturing systems that allows two or more APIs to be continuously manufactured on one portable modular machine, with a reasonable clean and changeover process.

Our mission is ever present - Continuity Pharma exists to ensure availability of essential medicines for patients.